Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Zscaler Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $358.46 (market cap $9.43B), while Zscaler Inc trades at $177.43 (market cap $28.87B). The key difference: Zscaler Inc is far larger — about 3.1× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals.
| BIO | ZS | |
|---|---|---|
Market Cap | $9.43B | $28.87B |
Sector | Health | Technology |
52-Week High | $356.25 | $336.27 |
52-Week Low | $241.71 | $118.05 |
Enterprise Value | $9.18B | $27.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $357.58, up 0.86% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, the company reported a Q2 2026 earnings beat with EPS of $2.62 versus $1.75 expected, and net income for 2025 reached $759.9 million, a significant recovery from prior years. Analyst sentiment is positive with a consensus buy rating and a $350 price target, though the P/E ratio of 43.39 suggests a premium valuation.
The outlook for BIO is cautiously optimistic, driven by earnings momentum and improving cash flow, but risks include high valuation, competitive pressures in life sciences, and reliance on academic research markets. Upside potential exists if international revenue trends strengthen, but investors should monitor margin sustainability and debt levels, which have improved but remain a focus.
Zscaler (ZS) trades at $176.11, showing modest daily movement. The stock exhibits a bullish technical trend with strong analyst support, evidenced by 42 buy ratings and a consensus price target of $191.81. Recent earnings consistently beat expectations, with Q1 2026 EPS of $1.08 surpassing the $1.01 forecast. Revenue growth is robust, increasing from $1.1B in 2022 to $2.67B in 2025, though the company remains unprofitable with a net income margin of -2.44%.
The outlook is positive due to strong revenue growth, leadership in cloud security, and bullish analyst sentiment. Key risks include persistent unprofitability, high valuation multiples like a P/S of 8.94, and competitive pressures in the cybersecurity sector. The upcoming Q2 2026 earnings report on September 3, 2026, will be critical for validating growth trajectory and investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
